The global Attention Deficit Hyperactivity Disorder (ADHD) market size was USD 16.44 Billion in 2022 and is expected to register a revenue CAGR of 7% over the forecast period, according to the latest report by Reports and Data.The market revenue growth is mainly driven by the increasing prevalence of ADHD cases globally. According to the Centers for Disease Control and Prevention (CDC), around 6.1 million children in the United States were diagnosed with ADHD in 2016. Furthermore, the rising prevalence of ADHD in adults, especially among women, is also expected to contribute to market growth. The market is also anticipated to witness substantial growth opportunities in developing countries like China and India, where the prevalence of ADHD is increasing.
Another element driving market revenue growth is increased demand for effective ADHD treatments and medications. Stimulants, the most often prescribed drugs for the treatment of ADHD, dominate the ADHD pharmaceutical market. Non-stimulant medicines, such as Strattera, are also gaining popularity among patients because to their efficacy and lack of side effects.
Moreover, there will be a greater demand for non-pharmacological therapies such cognitive behavioral therapy (CBT), psychotherapy, and behavioral therapy. These therapies aim to improve an ADHD patient's behavior, social skills, and academic performance. The rising patient and healthcare professional knowledge of the benefits of these treatments is predicted to propel market revenue growth.
Additionally, government measures to raise public awareness of ADHD and provide access to treatment options are likely to support market revenue growth. The US Department of Health and Human Services, for example, founded the National Resource Center on ADHD, which provides information and services to patients, families, and healthcare professionals (HHS). The European ADHD Alliance, like the American ADHD Association, promotes improved treatment choices and strives to enhance the quality of life for persons with ADHD across Europe.
Get a sample of the report @ [URL]https://www.reportsanddata.com/download-free-sample/6221/[/URL]
Some Key Highlights from the Report
• Throughout the projection period, the clinical evaluation segment is projected to contribute the biggest revenue share. Clinical evaluation comprises a close examination of the patient's medical history, behaviors, and symptoms. Rating scales and diagnostic criteria are also used to determine if the subject meets the diagnostic criteria for ADHD. Clinical evaluations are typically performed by a licensed clinician, such as a psychologist, psychiatrist, or pediatrician. Clinical evaluation is predicted to see revenue increase due to rising prevalence of ADHD, expanding public awareness of the condition, and rising need for a reliable and accurate diagnosis. Furthermore, it is anticipated that the development of novel diagnostic tools and the accessibility of funding for clinical assessments would hasten market expansion.
To know more about the report @ [URL]https://www.reportsanddata.com/report-detail/attention-deficit-hyperactivity-disorder-market[/URL]